GT Biopharma financials
$6.88+1.10%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 | Q4 '23 Dec 31 | Q3 '23 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross profit | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross margin | — | — | — | — | — | — | — | — | — | — | — | — |
| Operating income | -$4.5M | -$2.8M | -$5.6M | -$3.4M | -$1.5M | -$1.9M | -$3.8M | -$3.6M | -$3.9M | -$3.1M | -$3.2M | -$3.1M |
| Net income | -$4.6M | -$3.4M | -$28.9M | $4.1M | -$30.3M | -$776.0K | -$3.8M | -$3.4M | -$3.7M | -$2.3M | -$3.0M | -$2.4M |
| Net margin | — | — | — | — | — | — | — | — | — | — | — | — |
| Diluted EPS | $-3.00 | $-2.75 | $-62.44 | $26.00 | $-273.00 | $-8.25 | $-41.71 | $-38.25 | $-54.25 | $-41.00 | $-46.23 | $-44.25 |
| EBITDA | -$4.5M | -$2.8M | -$5.6M | -$3.4M | -$1.5M | -$1.9M | -$3.8M | -$3.6M | -$3.9M | -$3.1M | -$3.2M | -$3.1M |
| Operating cash flow | -$4.3M | -$2.5M | -$4.0M | -$3.7M | -$3.0M | -$2.2M | -$2.5M | -$2.7M | -$3.5M | -$4.2M | -$2.0M | -$2.0M |
| Free cash flow | -$4.3M | -$2.5M | -$4.0M | -$3.7M | -$3.0M | -$2.2M | -$2.5M | -$2.7M | -$3.5M | -$4.2M | -$2.0M | -$2.0M |
| Diluted shares | 1.6M | 1.2M | 0.5M | 0.2M | 0.1M | 0.1M | 0.1M | 0.1M | 0.1M | 0.1M | 0.1M | 0.1M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $5.0M | $8.9M | $6.8M | $2.5M | $5.2M | $2.4M |
| Short-term investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total assets | $5.8M | $10.0M | $8.1M | $4.3M | $7.1M | $2.7M |
| Total liabilities | $2.2M | $2.4M | $2.3M | $1.3M | $31.0M | $3.6M |
| Shareholders' equity | $3.6M | $7.6M | $5.8M | $3.0M | -$25.9M | -$980.0K |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology